Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 270

1.

Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity.

Kojima N, Biao L, Nakayama T, Ishii M, Ikehara Y, Tsujimura K.

J Control Release. 2008 Jul 2;129(1):26-32. doi: 10.1016/j.jconrel.2008.03.023. Epub 2008 Apr 7.

PMID:
18485512
2.

Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.

Ikehara Y, Shiuchi N, Kabata-Ikehara S, Nakanishi H, Yokoyama N, Takagi H, Nagata T, Koide Y, Kuzushima K, Takahashi T, Tsujimura K, Kojima N.

Cancer Lett. 2008 Feb 18;260(1-2):137-45.

PMID:
18077084
3.

Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.

Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ.

Clin Cancer Res. 1999 May;5(5):1173-82.

4.

An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.

Chamoto K, Wakita D, Narita Y, Zhang Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.

Cancer Res. 2006 Feb 1;66(3):1809-17.

5.

An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.

Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.

Int Immunol. 2006 Mar;18(3):425-34. Epub 2006 Jan 13.

PMID:
16415100
6.

Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.

Geary SM, Hu Q, Joshi VB, Bowden NB, Salem AK.

J Control Release. 2015 Dec 28;220(Pt B):682-90. doi: 10.1016/j.jconrel.2015.09.002. Epub 2015 Sep 8.

7.

Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice.

Johnston D, Reynolds SR, Bystryn JC.

Cancer Immunol Immunother. 2006 Apr;55(4):412-9. Epub 2005 Sep 6.

PMID:
16151809
9.

Archaeosomes as self-adjuvanting delivery systems for cancer vaccines.

Krishnan L, Dennis Sprott G; Institute for Biological Sciences, National Research Council of Canada.

J Drug Target. 2003;11(8-10):515-24.

PMID:
15203920
10.

Immunotherapy with oligomannose-coated liposomes ameliorates allergic symptoms in a murine food allergy model.

Kawakita A, Shirasaki H, Yasutomi M, Tokuriki S, Mayumi M, Naiki H, Ohshima Y.

Allergy. 2012 Mar;67(3):371-9.

PMID:
22423374
11.

Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery.

Yamasaki Y, Ikenaga T, Otsuki T, Nishikawa M, Takakura Y.

Vaccine. 2007 Jan 2;25(1):85-91. Epub 2006 Jul 31.

PMID:
16956699
12.

A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.

Suzuki R, Oda Y, Utoguchi N, Namai E, Taira Y, Okada N, Kadowaki N, Kodama T, Tachibana K, Maruyama K.

J Control Release. 2009 Feb 10;133(3):198-205. doi: 10.1016/j.jconrel.2008.10.015. Epub 2008 Oct 31.

PMID:
19000727
13.

The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling.

Met O, Wang M, Pedersen AE, Nissen MH, Buus S, Claesson MH.

Cancer Lett. 2006 Jan 18;231(2):247-56.

PMID:
16399226
14.
15.

Intranasal immunization with poly(╬│-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity.

Matsuo K, Koizumi H, Akashi M, Nakagawa S, Fujita T, Yamamoto A, Okada N.

J Control Release. 2011 Jun 10;152(2):310-6. doi: 10.1016/j.jconrel.2011.03.009. Epub 2011 Mar 22.

PMID:
21402114
16.

Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor.

Makki A, Weidt G, Blachere NE, Lefran├žois L, Srivastava PK.

Cancer Immun. 2002 Apr 16;2:4.

17.

Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment.

Bathe OF, Dalyot-Herman N, Malek TR.

BMC Cancer. 2003 Jul 28;3:21.

18.

Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization.

Ishii M, Kojima N.

Glycoconj J. 2010 Jan;27(1):115-23. doi: 10.1007/s10719-009-9263-8. Epub 2009 Oct 9.

PMID:
19816665
20.

CD8+ T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbumin in C57BL/6 mice.

Becerra JC, Arthur JF, Landucci GR, Forthal DN, Theuer CP.

Surgery. 2003 Apr;133(4):404-10.

PMID:
12717358

Supplemental Content

Support Center